环氧德克斯复合物中弗拉万衍生物的分子亲位活性:对抗癌疗法的新影响
Angelika A Adamus-Grabicka1, Pawel Hikisz2, Artur Stepniak3
1Department of Bioinorganic Chemistry, Faculty of Pharmacy, Medical University of Lodz, Muszynskiego 1, 90-151 Lodz, Poland.
International journal of molecular sciences
|August 10, 2024
概括
这项研究揭示了flavanone和chromanone衍生物,特别是它们的spiro-1-pyrazoline形式,表现出显著的抗癌活性. 反应性氧物种 (ROS) 在它们的亲细胞亡效应和细胞毒性中起着关键作用.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 弗拉瓦,克罗曼及其螺旋-1-pyrazoline衍生物是具有潜在生物活性的化合物类别.
- 了解它们的抗增殖作用背后的分子机制对于药物开发至关重要.
研究的目的:
- 评价flavanones,chromanones及其螺旋-1-pyrazoline衍生物和包括复合物的抗增殖潜力.
- 阐明反应性氧物种 (ROS) 在这些化合物的细胞毒性和亲亡活性中的作用.
- 评估这些化合物对凝血通路和红细胞 (RBC) 的影响.
主要方法:
- 分析线粒体潜力和死/亡细胞部分.
- 使用光探头来检测反应性氧物种 (ROS) 的产生.
- 对红血细胞进行血栓时间 (TT),质血栓时间 (PT),激活的部分血栓等离子体时间 (APTT),血液溶解和显微镜研究的测试.
主要成果:
- 反应性氧物种 (ROS) 的产生显著促进了flavanone模拟复合物的抗癌活性.
- 该研究分析了对线粒体潜力和细胞死亡途径 (亡/亡) 的影响.
- 评估了对凝血参数 (TT,PT,APTT) 和红细胞完整性的影响.
结论:
- 弗拉瓦和克罗曼衍生物,特别是螺旋-1-pyrazoline合物,具有显著的抗增殖和亲子亡潜力.
- 活性氧物种 (ROS) 是其抗癌作用的关键媒介.
- 需要进一步调查它们关于凝血和红细胞的安全性.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
The Extrinsic Apoptotic Pathway
6.3K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.3K


